O. Barbarash

发表

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.

David McDermott, R. Figlin, R. Motzer, 2007, The New England journal of medicine.

GARFIELD-AF: risk profiles, treatment patterns and 2-year outcomes in patients with atrial fibrillation in Germany, Austria and Switzerland (DACH) compared to 32 countries in other regions worldwide

Roger A. Nadeau, Jonathan B Sumner, T. Furukawa, 2022, Clinical Research in Cardiology.

Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis

F. Magrini, G. Cavet, M. Weinblatt, 2012, Annals of the rheumatic diseases.

Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis.

P. Sørensen, G. Giovannoni, B. Stubinski, 2007, Clinical therapeutics.

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry

Mehrad Amin Eskandari, J. F. Tinto, A. Capucci, 2018, Indian heart journal.

Safety and immunogenicity of a new formulation of interferon β-1a (Rebif® New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results

B Stubinski, G Giovannoni, G. Giovannoni, 2009, Multiple sclerosis.

Cause of Death and Predictors of All‐Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF

G. Breithardt, H. Crijns, P. Mclaughlin, 2016, Journal of the American Heart Association.

Risk factors associated with the development of death events during the first year of follow-up after pulmonary thromboembolism

A. Potapenko, E. Gorbunova, O. Barbarash, 2019, Medical Council.

INTERNATIONAL EPIDEMIOLOGICAL STUDY OF NONCOMMUNICABLE DISEASES IN RUSSIA: PROTOCOL

O. Barbarash, S. Maksimov, G. Artamonova, 2018, Complex Issues of Cardiovascular Diseases.

IIIb study in patients with relapsing multiple sclerosis : 96-week results-1 a ( Rebif ® New Formulation ) in a Phase β Safety and immunogenicity of a new formulation of interferon

G. Giovannoni, B. Stubinski, G. Pardo, 2009 .

Risk Factors, Clinical Features of the Course of Myocardial Infarction and Treatment of Young Patients Based on Two Hospital Registries

I. S. Bykova, O. Barbarash, O. Barbarash, 2020 .

Immune Response and Lipid Metabolism Gene Polymorphisms Are Associated with the Risk of Obesity in Middle-Aged and Elderly Patients

O. Barbarash, V. Minina, A. Ponasenko, 2022, Journal of personalized medicine.

Reduced immunogenicity with a new formulation of interferon-beta-1a (Rebif (R)): 24-week results of a phase IIIb study

P. Sørensen, G. Giovannoni, B. Stubinski, 2006 .

PCSK9 inhibitors for in-hospital treatment of patients with acute coronary syndrome and severe lipid metabolism disorders

O. Barbarash, O. Barbarash, V. Kashtalap, 2020, Russian Journal of Cardiology.

Cardioversion in patients with newly diagnosed non-valvular atrial fibrillation: observational study using prospectively collected registry data

Pedro F. Campos, Roger A. Nadeau, Jonathan B Sumner, 2021, BMJ.

Somatic genome variations in vascular tissues and peripheral blood leukocytes in patients with atherosclerosis

M. Nazarenko, O. Barbarash, O. Barbarash, 2014, Russian Journal of Genetics.

Association of mitochondrial DNA polymorphism with myocardial infarction and prognostic signs for atherosclerosis

I. A. Goncharova, R. R. Salakhov, O. Barbarash, 2015, Molecular Biology.

GARFIELD-AF: risk profiles, treatment patterns and 2-year outcomes in patients with atrial fibrillation in Germany, Austria and Switzerland (DACH) compared to 32 countries in other regions worldwide

Roger A. Nadeau, Jonathan B Sumner, T. Furukawa, 2022, Clinical Research in Cardiology.

Safety and immunogenicity of a new formulation of interferon beta-1a (Rebif (R) new formulation) in a phase IIIb study in patients with relapsing multiple sclerosis: 96-week results

G. Giovannoni, B. Stubinski, G. Pardo, 2008 .